Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
May 13, 2005
OXiGENE Announces Presentation at ASCO of Positive Tumor Response Data in Phase Ib Trial of CA4P With Chemotherapy

Clinical Investigator Reports that CA4P in Combination with Carboplatin and/or Paclitaxel Indicates Anti-tumor Activity and No Unexpected Toxicity WALTHAM, Mass.--(BUSINESS WIRE)--May 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN...

Apr 27, 2005
OXiGENE Reports First-Quarter 2005 Operational and Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--April 27, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN): Recent Accomplishments: Announced positive data supporting clinical p...

Apr 19, 2005
OXiGENE Announces Positive New Preclinical Safety and Efficacy Data for CA4P at AACR

WALTHAM, Mass.--(BUSINESS WIRE)--April 19, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN): -CA4P in Combination Treatment Causes Complete Remissions in Anaplastic Thyroid Preclinical Model- ...

Apr 18, 2005
OXiGENE Announces New Preclinical Data Presented at AACR Supporting Development of Lead Vascular Targeting Agents; OXi4503 Shows Promising Preclinical Efficacy Data in Colorectal Tumors

CA4P's Safety Profile Further CharacterizedWALTHAM, Mass., Apr 18, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the presentation of positive new preclinical data at the 96th Annual Meeting of the American Association of Cancer ...

Apr 15, 2005
OXiGENE to Webcast First-Quarter 2005 Financial Results Conference Call April 27; Live Webcast to be Available at www.oxigene.com

WALTHAM, Mass.--(BUSINESS WIRE)--April 15, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's first-quarter 2005 financial results conference call at 10:00 a.m. ET Wednesday, April 27, 2005. President and Chief Executive Officer Fred Driscoll, Chief Financial Officer James Murph...

Apr 13, 2005
OXiGENE Announces Presentations on Lead Vascular Targeting Agents at American Association of Cancer Research

Seven Poster Presentations on CA4P and OXi4503 at AACR WALTHAM, Mass.--(BUSINESS WIRE)--April 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the topics and schedules for seven poster presentations on OXiGENE compounds at the 96th Annual Meetin...

Mar 30, 2005
OXiGENE to Present at Lehman Brothers Eighth Annual Global HealthCare Conference: April 1st Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--March 30, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present at Lehman Brot...

Mar 25, 2005
OXiGENE, Inc. Adopts Stockholder Rights Plan

WALTHAM, Mass.--(BUSINESS WIRE)--March 25, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today that its Board of Directors has adopted a Stockholder Rights Plan (the "Rights Plan") that is designed to strengthen the ability of the Board of Directors to protect OXiGENE's stockholders. The Rights Plan was not adopted in response to an...

Mar 4, 2005
OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that Chief Scientific Officer, Dai Chaplin, will present at the 3rd International Symp...

Mar 4, 2005
OXiGENE Announces Sale of $15 Million of Common Stock

WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the Company will receive gross proceeds of $15 million from the sale of 3,336,117 shares of its common stock, pursuant to OXiGENE's effective shelf registration statement filed in October 2003. The shares are being sold to certain inst...

FirstPrevious
...
34
NextLast
= add release to Briefcase